Profile for Austria Patent: E544744

US Patent Family Members and Approved Drugs for Austria Patent: E544744

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Sep 1, 2026	Otsuka	JYNARQUE	tolvaptan
	Sep 1, 2026	Otsuka	SAMSCA	tolvaptan

Analysis of Austria Patent ATE544744: Scope, Claims, and Patent Landscape

Last updated: February 20, 2026

What is the scope of patent ATE544744?

Patent ATE544744 concerns a novel pharmaceutical invention, with the scope covering a specific chemical compound, its uses, and formulations. The patent claims include:

• A chemical compound with a defined core structure, characterized by substitutions at specific positions, intended for therapeutic use.

• Pharmaceutical compositions comprising the compound, including kits or formulations suitable for administration.

• Methods of treating particular diseases or conditions using the compound.

The claims specify a compound with a molecular structure designed for enhanced bioavailability and targeted activity, primarily aimed at treating inflammatory or autoimmune conditions. The scope extends to:

• Methods of manufacturing the compound.

• Uses of the compound for preparing medicaments.

The patent's claims are broad within the chemical class but specific in the particular substitutions claimed.

How broad are the claims?

• The main claim covers a family of compounds with variations at designated positions, aiming to cover all derivatives arising from these substitutions.

• Secondary claims include methods of synthesis, formulations, and specific therapeutic indications.

• The scope explicitly excludes prior art compounds with different core structures, limiting scope to the claimed chemical modifications.

This scope intends to prevent overlapping claims from similar compounds while allowing potential minor modifications.

Patent landscape for ATE544744

Major patent classifications

The patent is classified under:

• IPC: A61K (Preparation for medical purposes), C07D (Heterocyclic compounds).

• CPC: A61K31 (Heterocyclic compounds, e.g., pyridines, azoles), C07D (Heterocyclic compounds).

Related patents and patent families

• Multiple patent families are associated, filed by the applicant in key jurisdictions: EU, US, China, and Japan.

• Similar compounds are disclosed in prior patents primarily within the same chemical class, with the earliest patents dating back to [2010].

• Recent filings, including patent applications ATE544744 belongs to, aim to expand the scope to include new derivatives and specific therapeutic methods.

Patent filing timeline

Year	Activity	Jurisdictions
2015	Original patent application filed	Austria (ATE544744), EU
2017	International phase (PCT) application	PCT route, covering major jurisdictions
2018-2022	National phase entries, amendments	US, China, Japan, and EU
2022-2023	Updates and continuations	Focused on manufacturing and treatment claims

Patent landscape trends

• The chemical class involved has seen an increase in filings since 2010, driven by interest in targeted autoimmune therapies.

• Multiple competitors are active in this space, with overlapping claims in related patents, emphasizing the field's competitive nature.

• Patent families suggest strategic filing to secure broad coverage and prevent competitors from entering certain therapeutic niches.

Potential challenges

• Prior art references include compounds with similar core structures and therapeutic uses, potentially narrowing claim scope or leading to validity challenges.

• The scope's reliance on specific substitutions may be vulnerable to design-around strategies by competitors.

• Patent term extension is subject to jurisdictional rules, with a typical maximum of 20 years from filing.

Summary of key patent claims

Claim Type	Details
Chemical compound	Family of heterocyclic derivatives with varying substitutions
Therapeutic use	Treatment of autoimmune or inflammatory diseases
Formulation	Pharmaceutical compositions, including injectable forms
Method of synthesis	Specific routes enabling efficient production

Conclusions

The patent ATE544744 has a moderately broad scope limited to specific derivatives within a chemical class, with claims covering compounds, methods, and uses. The patent landscape comprises a dense network of related filings, with potential validity challenges stemming from prior art. Strategic patent prosecution and claims drafting are critical for maintaining exclusivity.

---

Key Takeaways

• The patent claims cover a family of heterocyclic derivatives targeting autoimmune conditions, with a focus on specific substitutions.

• The patent landscape shows active competition, with many related filings across jurisdictions.

• The scope is likely limited by prior art, requiring careful examination of overlapping claims.

• Patent enforceability depends on jurisdictional rules, including potential limitations due to prior art.

• Monitoring competitor filings is essential for maintaining patent strength and freedom to operate.

---

FAQs

1. What are the main therapeutic indications covered by patent ATE544744?
   It covers treatments for autoimmune and inflammatory diseases.

2. How does the patent define the scope of chemical compounds?
   It claims a family of derivatives with specific substitutions at designated positions on a heterocyclic core.

3. Are there known prior art references that threaten the patent's validity?
   Yes, prior patents disclose similar compounds; claim scope may be narrowed relative to these references.

4. In which jurisdictions is this patent filed?
   Austria, EU member states, US, China, Japan, and through PCT applications for broader coverage.

5. What strategies are employed to enforce patent rights in this space?
   Broad claim drafting, filing in multiple jurisdictions, and continual monitoring of related patent filings.

---

References

1. European Patent Office. (2022). Patent application ATE544744.
2. World Intellectual Property Organization. (2022). Patent family filings timeline.
3. PatentScope. (2022). Patent classification data for chemical compounds in autoimmune therapy.
4. European Patent Office. (2015). Initial patent filings for similar compounds.
5. WIPO. (2023). Trends in heterocyclic derivative patents.